Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Current Deferred Revenue (2016 - 2022)

Usana Health Sciences (USNA) has disclosed Current Deferred Revenue for 10 consecutive years, with $19.6 million as the latest value for Q1 2022.

  • Quarterly Current Deferred Revenue rose 23.09% to $19.6 million in Q1 2022 from the year-ago period, while the trailing twelve-month figure was $19.6 million through Jan 2022, up 23.09% year-over-year, with the annual reading at $19.6 million for FY2022, 23.09% up from the prior year.
  • Current Deferred Revenue for Q1 2022 was $19.6 million at Usana Health Sciences, up from $16.0 million in the prior quarter.
  • The five-year high for Current Deferred Revenue was $19.6 million in Q1 2022, with the low at $2.6 million in Q4 2018.
  • Average Current Deferred Revenue over 4 years is $13.0 million, with a median of $14.9 million recorded in 2019.
  • The sharpest move saw Current Deferred Revenue dropped 13.61% in 2018, then surged 423.51% in 2019.
  • Over 4 years, Current Deferred Revenue stood at $2.6 million in 2018, then soared by 423.51% to $13.9 million in 2019, then increased by 15.16% to $16.0 million in 2021, then increased by 23.09% to $19.6 million in 2022.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $19.6 million, $16.0 million, and $13.9 million for Q1 2022, Q1 2021, and Q4 2019 respectively.